NewsRoom Articles - Page 42 of 256

TuesdayAug 10, 2021 11:38 am

Flora Growth Corp. (NASDAQ: FLGC) Inks 2 LOIs to Boost CBD Product Distribution in Australia, Latin America

Flora Growth Corp. is a Colombian cannabis cultivator that is building a global cannabis CPG portfolio of premium brands and products Flora Growth recently announced an LOI designed to grant it an in-road to Australia’s over-the-counter medical cannabis and CBD commercial markets The company also signed an LOI to distribute popular Canadian pain topical brand KaLaya throughout Latin American countries, with exports planned to the United States, and to infuse its established line of products with CBD Market analysts predict Australia’s medial cannabis market will explode from about $150 million this year to more than a billion dollars by 2025…

MondayAug 09, 2021 2:18 pm

BevCanna Enterprises Inc. (CSE: BEV) (OTCQB: BVNNF) (FSE: 7BC) Subsidiary Inks Deal to Provide Limited-Edition Alkaline Spring Water to BC Firefighters

Naturo Group signs contract with BC Wildfire Services Division; will provide special bottled water to over 1,100 firefighters across British Columbia. TRACE-branded natural 7.7ph alkaline spring water is sourced directly the source in British Columbia, the very land the firefighters protect. BevCanna’s TRACE product line features unique, ancient minerals that offer a broad range of wellness properties including cognitive performance, immune function and gut health. BevCanna Enterprises (CSE: BEV) (OTCQB: BVNNF) (FSE: 7BC) has announced that its wholly owned subsidiary Naturo Group has been selected to manufacture and supply a special, limited-edition run of its TRACE-branded, alkaline spring water to…

MondayAug 09, 2021 1:49 pm

Flora Growth Corp. (NASDAQ: FLGC) Receives Fair Value Estimate, Coverage from Argus Research Company; Developing Growth Opportunities by Columbia’s Cannabis Law, Headquarter Relocation

Flora Growth Corp recently received coverage from Argus Research, which gives the company’s stock a fair value estimate of $7.50 against the $3.24 recorded July 20 Argus also projects that Flora’s revenue would increase to $9 million in 2021 and $31 million in 2022, up from $0.1 million reported in 2020 Flora received a boost in its operations when Colombia’s president accepted and signed reforms to the existing cannabis legislation The updated law allows for the manufacture, sale and export of psychoactive (high-THC) cannabinoid ingestible and medical products and removes marketing limitations on cannabis products in Colombia Flora is also…

MondayAug 09, 2021 1:05 pm

InMed Pharmaceuticals Inc. (NASDAQ: INM) and Its Quest to Build an Industry-Leading, Rare Cannabinoid Enterprise

InMed announced a non-binding letter of intent to acquire BayMedica Inc. The move is designed to grow InMed’s market presence and strengthen its operations The two companies have had a reciprocal research collaboration that dates back to November 2020 InMed looks to capitalize on the growing cannabinoid industry that is projected to grow at a CAGR of 21.2% from 2021 to 2028 InMed Pharmaceuticals (NASDAQ: INM) is a clinical-stage company committed to developing cannabinoid-based pharmaceutical drug candidates. It also manufactures technologies for pharmaceutical-grade rare cannabinoids. It is known for creating a pipeline of cannabinoid-based pharmaceutical drug candidates to treat various…

FridayAug 06, 2021 9:30 am

First Results from Lexaria Bioscience Corp. (NASDAQ: LEXX) Study Show Marked Gains in Blood Pressure Reduction over Generic CBD Controls

Drug delivery platform developer Lexaria Bioscience has developed its patented DehydraTECH(TM) as a means of transforming pharmaceuticals that increases their bioavailability and speed of efficacy Ongoing testing of DehydraTECH in combination with cannabidiol (“CBD”) is analyzing DehydraTECH’s responsiveness to hypertension conditions that are targeted in heart disease and stroke therapies Partial results from the company’s first study indicate Lexaria’s DehydraTECH platform, when processed with CBD, reduces blood pressure and does so much more rapidly when compared with the generic CBD controls The complete results of the study will be produced as sample and data analyses work are completed Lexaria is…

FridayAug 06, 2021 9:00 am

RYAH Group Inc. (CSE: RYAH) Sees Important Trends in Sports Medicine and Plant-Therapy

As U.S. research restrictions are lifted there is a rising interest in the use of plant-therapy in sports medicine Cannabis in sports medicine took center stage at the Tokyo Olympics American athletes are turning more and more to cannabis as a pain reliever, alternative to opioids, and part of an overall sports recovery plan RYAH Group (CSE: RYAH) (formerly RYAH Medtech), the leader in dose-control technology for plant-based medicine, works with researchers to provide a full turnkey solution for clinical studies from start to finish. RYAH Group's dose-control devices standardize the dosing protocol, QR products ensure compliance, and mobile apps…

ThursdayAug 05, 2021 1:16 pm

Grapefruit USA Inc. (GPFT) Signs Agreement with Leading Canadian Cannabis Manufacturer to Offer Game-Changing THC/CBD Cream

GPFT forms strategic alliance with 6PAK Solutions Inc Company working to achieve goal of launching Hourglass in Canada in the third quarter of 2021 Grapefruit’s patented Hourglass delivery cream system has fundamentally changed the way humans absorb cannabinoids In the United States, Grapefruit USA (OTCQB: GPFT) provides consumers with one of the most effective cannabis topical creams on the market. Now, through its partnership with 6PAK Solutions Inc., Grapefruit can offer its patented Hourglass(TM) Time Release THC+CBD Delivery Topical Relief Cream in Canada too (https://cnw.fm/qeAd5). “We are very encouraged by 6PAK’s decision to form an alliance with Grapefruit to take…

WednesdayAug 04, 2021 12:05 pm

Grapefruit USA Inc. (GPFT) Expands into Billion-Dollar Market with New CBD Pet Tincture

Pet CBD industry projected to reach $1.7 billion by 2025 GPFT’s new pet CBD product targets two common dog, cat ailments: anxiety and joint pain Pets deserve the same relief that their owners experience with Grapefruit’s CBD products, says CEO Humans aren’t the only ones who may benefit from all that cannabidiol (“CBD”) offers. A recent Brightfield Group article reported that the pet CBD industry has experienced significant growth over the last several years, with Brightfield projecting an expected market valuation of more than $1.7 billion by 2025 (https://cnw.fm/drv6i). Grapefruit USA (OTCQB: GPFT) is leveraging its expertise in the space…

WednesdayAug 04, 2021 11:11 am

RYAH Group Inc. (CSE: RYAH) Supporting U.S. Changes in Cannabis Research

New cultivators have approved for federally funded studies in the U.S., and 575 DEA-licensed researchers are standing by, ready for the change RYAH's ecosystem of products allows data to be collected from seed to consumption, providing a holistic view of the plant necessary for optimal research RYAH continues to expand its global clinical and distribution network for plant-based medicine and digital patient care The U.S. is putting an end to its 50-year long prohibition on Cannabis Research (https://cnw.fm/UOoHf). New cultivators have now been approved for federally funded studies. With over 575 DEA-licensed researchers across the U.S., the future of cannabis…

TuesdayAug 03, 2021 9:30 am

InMed Pharmaceuticals Inc. (NASDAQ: INM) Is ‘One to Watch’

InMed has a world class leadership team with a successful track record of drug development and commercialization The company recently announced closing of a $12 million private placement InMed has a solid and expanding intellectual property portfolio with multiple patents filed The company recently signed an LOI to acquire rare cannabinoids manufacturer BayMedica InMed retains all commercial rights to its IntegraSyn manufacturing system InMed has filed clinical trial applications in several countries as part of a Phase 2 clinical trial of INM-755 (cannabinol) cream in epidermolysis bullosa The consumer market for cannabinoid-based pharmaceuticals in the United States is forecast to…

News and publishing service for CBD related companies

Contact us: 512.354.7000